Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Board Change

26 Jan 2023 08:00

Arix Bioscience PLC (ARIX)


Board Change

26-Jan-2023 / 07:00 GMT/BST

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

The issuer is solely responsible for the content of this announcement.


Arix Bioscience plc

Board Change

London, 26 January 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, today announces Dr Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.

Peregrine Moncreiffe, Chairman of Arix, commented: “On behalf of the Board, I would like to thank Benny for the support he has shown to the Company since joining the Board last year and wish him well in his future endeavours.”

[ENDS]

 

For more information, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

 

About Arix Bioscience plc

 

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 



ISIN: GB00BD045071
Category Code: BOA
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 218423
EQS News ID: 1543761

 
End of Announcement EQS News Service


fncls.ssp?fn=show_t_gif&application_id=1543761&application_name=news&site_id=london_south_east
Date   Source Headline
1st Oct 20202:40 pmEQSLogicBio announces pricing of public offering
21st Sep 202011:20 amEQSHardman & Co Research: Arix Bioscience (ARIX): Realising the valuation disconnect
18th Sep 20208:57 amEQSArix Bioscience PLC: Autolus presents additional AUTO3 data in DLBCL
8th Sep 20207:00 amEQSArix Bioscience PLC: Interim Results for the Six Months Ended 30 June 2020
13th Aug 20207:07 amPRNNotice of Results
10th Aug 202012:49 pmPRNLogicBio announces IND clearance for LB-001
31st Jul 20202:06 pmRNSSecond Price Monitoring Extn
31st Jul 20202:00 pmRNSPrice Monitoring Extension
31st Jul 20207:01 amPRNTotal Voting Rights
20th Jul 20201:28 pmPRNAmplyx announces positive Phase 2 data
10th Jul 20207:53 amPRNAtox Bio plans NDA submission for Q3 2020
8th Jul 20201:27 pmPRNVelosBio completes $137 million Series B financing
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
1st Jul 20207:00 amPRNDirector/PDMR Shareholding, Issue of Ordinary Shares
12th Jun 20202:24 pmPRNAura presents updated AU-011 clinical data at ARVO 2020
12th Jun 20201:34 pmPRNImara presents positive interim Phase 2a data at EHA
12th Jun 20209:13 amPRNAutolus AUTO1 and AUTO3 data at EHA
8th Jun 20207:08 amPRNArix announces strategic and operational update
4th Jun 20205:42 pmPRNResults of Annual General Meeting
1st Jun 20202:57 pmPRNIterum announces topline Phase 3 data in complicated UTI
29th May 20201:38 pmPRNHarpoon presents interim Phase 1 data for HPN424
29th May 20201:06 pmPRNAutolus presents additional AUTO3 data in DLBCL
27th May 20204:40 pmRNSSecond Price Monitoring Extn
27th May 20204:35 pmRNSPrice Monitoring Extension
20th May 20207:00 amPRNAmplyx closes $53 million Series C extension
19th May 20209:35 amEQSHardman & Co Research: Arix Bioscience (ARIX): 1Q'20 portfolio update
12th May 20207:00 amPRNNotice of Annual General Meeting
28th Apr 20209:23 amPRNPharmaxis announces new data in myelofibrosis
27th Apr 20201:12 pmPRNHarpoon doses first patient in multiple myeloma trial
23rd Apr 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): Resetting the stage
17th Apr 20202:59 pmPRNDirector/PDMR Shareholding
16th Apr 20201:08 pmPRNAutolus announces FDA acceptance of IND application
6th Apr 20207:00 amPRNChanges to Board of Directors and executive leadership
19th Mar 202010:31 amEQSHardman & Co Research: Arix Bioscience (ARIX): Fiscal 2019 - moving with the times
16th Mar 20207:00 amPRNDirector/PDMR Shareholding
12th Mar 20207:11 amPRNImara prices Nasdaq IPO
10th Mar 20207:00 amPRNAnnual Results for the year ended 31 December 2019
9th Mar 202012:00 pmPRNDr Roberto Iacone appointed as EiR
3rd Mar 202012:18 pmPRNUpdate on Imara proposed IPO in the United States
3rd Mar 20207:30 amEQSHardman & Co Research: Q&A with Q&A with Dr Dorothea Hill on Arix Bioscience (ARIX)
27th Feb 202012:00 pmPRNNotice of Results
24th Feb 20201:26 pmPRNAura announces updated Phase 1b/2 clinical data
19th Feb 20207:30 amEQSHardman & Co Research: Arix Bioscience (ARIX) - Initiation of coverage: With high risk can come high reward
17th Feb 20207:00 amPRNImara files for proposed IPO in the United States
30th Jan 202012:08 pmPRNAutolus presents encouraging additional AUTO3 data
27th Jan 20207:00 amPRNArix co-founds Quench Bio with Series A financing
23rd Jan 20207:00 amPRNAutolus announces pricing of public offering
17th Jan 20201:15 pmPRNIterum announces $52 million private placement
18th Dec 201910:00 amPRNPharmaxis business update
17th Dec 201910:57 amPRNBoard changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.